scispace - formally typeset
C

Corrado Pipan

Researcher at University of Udine

Publications -  42
Citations -  1327

Corrado Pipan is an academic researcher from University of Udine. The author has contributed to research in topics: Hepatitis C virus & Viral load. The author has an hindex of 16, co-authored 40 publications receiving 1234 citations. Previous affiliations of Corrado Pipan include University of Bologna.

Papers
More filters
Journal ArticleDOI

Prevalence of hepatitis C virus infection in patients with lymphoproliferative disorders.

TL;DR: The close association between HCV infection and EMC is confirmed, and evidence is provided that the pathological substrate of EMC corresponds to the immunocytoma in HCV-positive lymphomas clinically behave as essential mixed cryoglobulinemia.
Journal ArticleDOI

Vitamin D supplementation improves response to antiviral treatment for recurrent hepatitis C.

TL;DR: In conclusion, vitamin D deficiency predicts an unfavourable response to antiviral treatment of RHC and vitamin D supplementation improves the probability of achieving a SVR following antiviral therapy.
Journal ArticleDOI

Hepatitis C virus infection among cryoglobulinemic and non-cryoglobulinemic B-cell non-Hodgkin's lymphomas

TL;DR: Close association between HCV infection and cryoIg production, already described in mixed cryoglobulinemia, is confirmed also among B-cell NHL, and low-grade lymphomas are the most frequent HCV-related lymphomas.
Journal ArticleDOI

Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia.

TL;DR: Quantification of WT1 in bone marrow samples may be useful as a marker of minimal residual disease (MRD) and may predict the relapse of AML after allogeneic hematopoietic stem cell transplant (HSCT).
Journal ArticleDOI

Chronic Hepatitis C Virus Infection After Treatment for Pediatric Malignancy

TL;DR: The prevalence of HCV infection was high in patients who were treated for a childhood malignancy and, after a 14-year median follow-up, chronic liver disease of anti-HCV+ positive patients did not show progression to liver failure.